An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02832167
Phase
PHASE2
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to determine whether nivolumab is an effective treatment for cancer that has advanced or has spread. Various tumor types may be eligible for enrollment.

Key Dates

Start date
Feb 22, 2016
Status verified
Apr 2022
Primary completion
Oct 20, 2019
Completion
Jun 24, 2021

Study Design

Enrollment
239 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: From first dose to the date of objectively documented progression (per tumor-specific response criteria) or the date of subsequent therapy, whichever occurs first (up to approximately 24 months) ]

Locations (39)

FacilityCityStateZIPSite coordinators
Arizona Oncology Associates, PCTucsonArizona85711-
CBCC Global Research, Inc. at Comprehensive Blood and Cancer CenterBakersfieldCalifornia93309-
St. Jude Hospital Yorba LindaFullertonCalifornia92835-
LACNLos AngelesCalifornia90017-
UCLA Main Campus - University California Los AngelesLos AngelesCalifornia90095-
Torrence Health Association, DBA Torrance Memorial;Physician Network/Cancer Care AssociatesRedondo BeachCalifornia90277-
Coastal Integrative Cancer CareSan Luis ObispoCalifornia93401-
Cancer Center of Santa Barbara with Sansum ClinicSanta BarbaraCalifornia93105-
Central Coast Medical Oncology CorporationSanta MariaCalifornia93454-
Rocky Mountain Cancer Centers - Denver MidtwonDenverColorado80218-
St. Mary's Hospital And Regional Medical CenterGrand JunctionColorado81501-
Memorial Healthcare SystemHollywoodFlorida33021-
Florida Cancer AffiliatesOcalaFlorida34471-
Orlando Health, IncOrlandoFlorida32806-
Florida Cancer Specialists & Research InstituteSt. PetersburgFlorida33705-
Florida Cancer SpecialistsWest Palm BeachFlorida33401-
Illinois Cancer SpecialistsNilesIllinois60714-
Fort Wayne Medical Oncology and Hematology, Inc.Fort WayneIndiana46845-
Maryland Oncology Hematology P.A.ColumbiaMaryland21044-
Minnesota Oncology Hematology, P.A.MinneapolisMinnesota55404-
HCA Midwest HealthcareKansas CityMissouri64132-
Oncology Hematology West P.C. dba Nebraska Cancer SpecialistsOmahaNebraska68130-
Texas Oncology-Austin CentralLas VegasNevada89148-
Saint Barnabas Medical Cancer CenterLivingstonNew Jersey07039-
USOR - New York Oncology Hematology, P.C.AlbanyNew York12206-
Hematology Oncology Associates, PCMedfordOregon97504-
Willamette Valley Cancer Institute and Research CenterSpringfieldOregon97477-
Northwest Cancer Specialists, P.C.TualatinOregon97062-
Greenville Health SystemGreenvilleSouth Carolina29615-
West Cancer CenterGermantownTennessee38138-
Tennessee OncologyLebanonTennessee37090-
Texas Oncology - Baylor Charles A. Simmons Cancer CenterDallasTexas75246-
Texas Oncology, P.A.Fort WorthTexas76104-
The University of Texas MD Anderson Cancer Center-mergeHoustonTexas77030-
Texas Oncology, P.A.San AntonioTexas78240-
Texas Oncology The WoodlandsThe WoodlandsTexas77380-
Texas Oncology - WacoWacoTexas76712-
Virginia Cancer Care Specialist, PCFairfaxVirginia22031-
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer CareWythevilleVirginia24382-

Find similar trials in Tucson, AZ

By research site
Arizona Oncology Associates, PC· Tucson, AZCBCC Global Research, Inc. at Comprehensive Blood and Cancer Center· Bakersfield, CASt. Jude Hospital Yorba Linda· Fullerton, CALACN· Los Angeles, CAUCLA Main Campus - University California Los Angeles· Los Angeles, CATorrence Health Association, DBA Torrance Memorial;Physician Network/Cancer Care Associates· Redondo Beach, CA

Related Studies